Civitas Announces Positive Results in Parkinson’s Drug Trial

The study showed that CVT-301 is safe and easily absorbed into the bloodstream, via the lungs, at levels that are likely to produce a therapeutic outcome.

US-based Civitas Therapeutics has announced that CVT-301, an inhaled drug for the treatment of Parkinson's disease, has shown positive results in a Phase I clinical trial.

The study showed that CVT-301, an inhaled formulation of levodopa (L-dopa) for the rapid relief from motor fluctuations, is safe and easily absorbed into the bloodstream, via the lungs, at levels that are likely to produce a therapeutic outcome.

Civitas co-founder and chief medical officer Martin Freed said that due to the unpredictability of oral L-dopa, the therapeutic rationale for using inhaled L-dopa to manage motor fluctuations in Parkinson's disease was intuitive but, until now, technically impractical.

"The Phase I d